Pharmacological treatment of heart failure with preserved ejection fraction

Yonago Acta Medica

Volumn 60, Issue 2, 2017, Pages 71-76

  Yamamoto, Kazuhiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Diastole; Heart failure; Pharmacological intervention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZOSEMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENKEPHALINASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISOSORBIDE MONONITRATE; IVABRADINE; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; RANOLAZINE; SACUBITRIL; SPIRONOLACTONE; TORASEMIDE; VALSARTAN;

DRUG EFFECT; DRUG EFFICACY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; JAPAN; NONHUMAN; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85021325126     PISSN: 05135710     EISSN: 13468049     Source Type: Journal    
DOI: 10.33160/yam.2017.06.001     Document Type: Review

References (54)

1. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720-6. PMID: 22936826.
2. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J. 2013;77:944-51. PMID: 23502987.
3. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, et al. Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016;9:e003116. PMID: 27266854.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9. PMID: 16855265.
5. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002;82:149-58. PMID: 11853901.
6. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res. 2005;68:118-27. PMID: 16002057.
7. Masuyama T, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012;76:833-42. PMID: 22451450.
8. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169:323-33. PMID: 25728721.
9. Borbely A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJM, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-81. PMID: 15699264.
10. van Heerebeek L, Borbely A, Niessen HWM, Bronzwaer JGF, van der Velden J, Stienen GJM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-73. PMID: 16618817.
11. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-in-dependent hypertrophy. J Am Coll Cardiol. 2001;37:293-9. PMID: 11153754.
12. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Miwa T, et al. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Cardiovasc Res. 2003;57:757-65. PMID: 12618237.
13. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension. 2004;43:686-91. PMID: 14757777.
14. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45. PMID: 16963472.
15. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67. PMID: 19001508.
16. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81. PMID: 13678871.
17. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108-17. PMID: 23188027.
18. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, et al. Prognostic value of baseline plasma ami-no-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRE-SERVE trial. Circ Heart Fail. 2011;4:569-77. PMID: 21715583.
19. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Reg-ul Integr Comp Physiol. 2007;292:R946-54. PMID: 17023667.
20. Binart N, Lombes M, Rafestin-Oblin M, Baulieu E. Characterization of human mineralocorticosteroid receptor expressed in the baculovirus system Proc Natl Acad Sci U S A. 1991;88:10681-5. PMID: 1660146.
21. Ohtani T, Mano T, Hikoso S, Sakata Y, Nishio M, Takeda Y, et al. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. J Hypertens. 2009;27:1074-83. PMID: 19349910.
22. Omori Y, Mano T, Ohtani T, Sakata Y, Takeda Y, Tamaki S, et al. Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL). Yonago Acta Med. 2014;57:109-16. PMID: 25349466.
23. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-61. PMID: 17372171.
24. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17:634-42. PMID: 21807324.
25. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation. 2004;110:558-65. PMID: 15277317.
26. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92. PMID: 24716680.
27. Butler J, Hamo CE, Udelson JE, Pitt B, Yancy C, Shah SJ, et al. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016;9:e003358. PMID: 27756791.
28. Tamaki S, Sakata Y, Mano T, Ohtani T, Takeda Y, Kamimura D, et al. Long-term beta-blocker therapy improves diastolic function even without the therapeutic effect on systolic function in patients with reduced ejection fraction. J Cardiol. 2010;56:176-182. PMID: 20493661.
29. Kobayashi M, Machida N, Mitsuishi M, Yamane Y. Beta-blocker improves survival, left ventricular function and myocardial remodeling in hypertensive rats with diastol- ic heart failure. Am J Hypertens. 2004;17:1112-9. PMID: 15607617.
30. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail. 2008;10:446-53. PMID: 18400557.
31. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospi-talization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150-8. PMID: 19497441.
32. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004;6:453-61. PMID: 15182771.
33. Yamamoto K, Redfield MM, Nishimura RA. Analysis of left ventricular diastolic function. Heart. 1996;75(Suppl 2):27-35. PMID: 8785701.
34. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110-8. PMID: 22983988.
35. Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One. 2014;9:e90555. PMID: 24599-93.
36. Yanagihara K, Kinugasa Y, Sugihara S, Hirai M, Yamada K, Ishida K, et al. Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction. J Cardiovasc Pharmacol. 2013;62:485-90. PMID: 24072178.
37. Dobre D, van Veldhuisen DJ, DeJongste MJ, Lucas C, Cleuren G, Sanderman R, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail. 2007;9:280-6. PMID: 17027334.
38. El-Refai M, Peterson EL, Wells K, Swadia T, Sabbah HN, Spertus JA, et al. Comparison of beta-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail. 2013;19:73-9. PMID: 23384631.
39. Shah R, Wang Y, Foody JM. Effect of statins, angioten-sin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol. 2008;101:217-22. PMID: 18178410.
40. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation. 2005;112:357-63. PMID: 16009792.
41. Grigorian Shamagian L, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR. Angioten-sin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail. 2006;12:128-33. PMID: 16520261.
42. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-block- ers in heart failure: findings from the OPTIMIZE-HF (Orga-nized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184-92. PMID: 19130987.
43. Farasat SM, Bolger DT, Shetty V, Menachery EP, Gerstenblith G, Kasper EK, et al. Effect of Beta-blocker therapy on rehos-pitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol. 2010;105:229-34. PMID: 20102924.
44. Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol. 2009;103:829-33. PMID: 19268740.
45. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008;102:1524-9. PMID: 19026308.
46. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. PMID: 16854724.
47. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-9. PMID: 18757089.
48. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, et al. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J. 2015;79:574-82. PMID: 25746542.
49. Alehagen U, Benson L, Edner M, Dahlstrom U, Lund LH. Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50. Circ Heart Fail. 2015;8:862-70. PMID: 26243795.
50. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015;373:2314-24. PMID: 26549714.
51. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2013;309:1268-77. PMID: 23478662.
52. Solomon SD, Zi le M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-95. PMID: 22932717.
53. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kos-mala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330-8. PMID: 23916925.
54. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1:115-22. PMID: 24621836.